Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) EBIT Margin (2022 - 2025)

Stoke Therapeutics has reported EBIT Margin over the past 4 years, most recently at 4382.24% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 432187.0% year-over-year to 4382.24%; the TTM value through Dec 2025 reached 11.16%, up 26614.0%, while the annual FY2025 figure was 11.16%, 26615.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 4382.24% at Stoke Therapeutics, down from 405.3% in the prior quarter.
  • Over five years, EBIT Margin peaked at 70.15% in Q1 2025 and troughed at 4382.24% in Q4 2025.
  • A 4-year average of 871.34% and a median of 727.04% in 2022 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: soared 99551bps in 2024 and later tumbled -432187bps in 2025.
  • Year by year, EBIT Margin stood at 831.58% in 2022, then dropped by -27bps to 1055.89% in 2023, then skyrocketed by 94bps to 60.37% in 2024, then crashed by -7158bps to 4382.24% in 2025.
  • Business Quant data shows EBIT Margin for STOK at 4382.24% in Q4 2025, 405.3% in Q3 2025, and 197.58% in Q2 2025.